Status:
ACTIVE_NOT_RECRUITING
Biomarkers and Choroidal Neovascularization
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Choroidal Neovascularization
Mineralocorticoid Excess
Eligibility:
All Genders
18-90 years
Brief Summary
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
Detailed Description
Age-related macular degeneration (AMD) is the most frequent cause of blindness in industrialized countries. Multiple molecular pathways have been implicated in the pathogenesis of choroidal neovascula...
Eligibility Criteria
Inclusion
- Patients of group 1:
- Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration
- Patients without intravitreal injection or last intravitreal injection \> 3 months
- Informed signed consent
- Patients of group 2:
- Patients without choroidal neovascularization
- Patients with intraocular surgery (cataract or vitrectomy surgery)
- Signed consent
Exclusion
- Myocardial infarction \< 12 months
- Chronic renal failure
- Inflammatory disease
- Infectious disease :HIV, viral hepatitis, tuberculosis
- Type 1 or 2 Diabetes
- Patients treated by mineralocorticoid antagonist treatment.
- Type 2 or 3 choroidal neovascularization
- Pregnant woman
Key Trial Info
Start Date :
July 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 6 2027
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04439708
Start Date
July 6 2020
End Date
July 6 2027
Last Update
April 25 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Ophtalmopole Hôpital Cochin
Paris, France, 75014
2
Hôpital Foch
Suresnes, France, 92150